A Phase 3 interventional study of Evolocumab and Ezetimibe in Hyperlipidemia, sponsored by Amgen. Completed at 244 sites in 21 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 4th largest by enrollment, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 9th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,067 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 9th registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.
Prior to the first randomization, participants entered a screening period to determine eligibility. During screening, all participants received subcutaneous placebo corresponding to the once monthly dose volume. Participants who completed the screening period and met eligibility criteria were randomized to 1 of 5 open-label statin cohorts (atorvastatin 10 mg or 80 mg, rosuvastatin 5 mg or 40 mg, or simvastatin 40 mg) for a 4 week lipid stabilization period based on statin therapy at the time of study entry (no statin use vs non-intensive statin use vs intensive statin use).
After the 4-week lipid-stabilization period, eligible patients taking rosuvastatin or simvastatin during the lipid-stabilization phase were then randomized to 1 of 4 treatment groups: evolocumab (140 mg, subcutaneous, every 2 weeks) or matching placebo (subcutaneous, every 2 weeks), or evolocumab (420 mg, subcutaneous, monthly) or matching placebo (subcutaneous, monthly). Patients taking atorvastatin during the lipid-stabilization phase were then randomized to 1 of 6 treatment groups: evolocumab (140 mg, subcutaneous, every 2 weeks) and placebo (oral, daily), evolocumab (420 mg, subcutaneous, monthly) and placebo (oral, daily), placebo (subcutaneous, every 2 weeks) and placebo (oral, daily) or ezetimibe (10 mg, oral, daily), or placebo (subcutaneous, monthly) and placebo (oral, daily) or ezetimibe (10 mg, oral, daily).
A participant was considered randomized into the study after successfully completing the screening period, meeting all inclusion/exclusion criteria, and undergoing both randomization procedures.
Participants randomized to simvastatin who were taking verapamil or diltiazem prior to randomization received simvastatin 10 mg once daily (QD) while participants who were taking amlodipine, amiodarone or ranolazine prior to randomization received simvastatin 20 mg QD. All other participants randomized to simvastatin received simvastatin 40 mg QD.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
This study's enrollment of 2,067 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hyperlipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Placebo to Ezetimibe · Drug: Atorvastatin
Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Placebo to Ezetimibe · Drug: Atorvastatin
Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once a day for up to 12 weeks.
Drug: Ezetimibe · Drug: Placebo to Evolocumab · Drug: Atorvastatin
Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
Drug: Ezetimibe · Drug: Placebo to Evolocumab · Drug: Atorvastatin
Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
Biological: Evolocumab · Drug: Placebo to Ezetimibe · Drug: Atorvastatin
Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks
Biological: Evolocumab · Drug: Placebo to Ezetimibe · Drug: Atorvastatin
Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Placebo to Ezetimibe · Drug: Atorvastatin
Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month and placebo tablets once a day for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Placebo to Ezetimibe · Drug: Atorvastatin
Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
Drug: Ezetimibe · Drug: Placebo to Evolocumab · Drug: Atorvastatin
Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
Drug: Ezetimibe · Drug: Placebo to Evolocumab · Drug: Atorvastatin
Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
Biological: Evolocumab · Drug: Placebo to Ezetimibe · Drug: Atorvastatin
Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
Biological: Evolocumab · Drug: Placebo to Ezetimibe · Drug: Atorvastatin
Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Rosuvastatin
Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Rosuvastatin
Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
Biological: Evolocumab · Drug: Rosuvastatin
Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
Biological: Evolocumab · Drug: Rosuvastatin
Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Rosuvastatin
Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Rosuvastatin
Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
Biological: Evolocumab · Drug: Rosuvastatin
Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
Biological: Evolocumab · Drug: Rosuvastatin
Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Simvastatin
Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Simvastatin
Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
Biological: Evolocumab · Drug: Simvastatin
Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
Biological: Evolocumab · Drug: Simvastatin
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Administered orally once a day
Also known as: Zetia
Administered by subcutaneous injection
Administered orally once a day
Administered orally once a day
Also known as: Lipitor
Administered orally once a day
Also known as: Crestor
Administered orally once a day
Also known as: Zocor
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Change From Baseline in LDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Non-HDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
Time frame: Baseline and Week 12
Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL
Time frame: Weeks 10 and 12
Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12
Time frame: Week 12
Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Lipoprotein(a) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Triglycerides at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in HDL-C at Week 12
Time frame: Baseline and Week 12
Adults aged 18 to 80 years with screening low-density lipoprotein cholesterol (LDL-C) ≥ 150 mg/dL (no statin at screening), ≥ 100 mg/dL (non-intensive statin at screening), or ≥ 80 mg/dL (intensive statin at screening) and fasting triglycerides ≤ 400 mg/dL. First patient enrolled on 15 January 2013; Last patient enrolled on 10 July 2013.
| Milestone | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 56 | 55 | 56 | 55 | 110 | 110 | 55 | 55 | 56 | 54 | 110 | 110 | 58 | 57 | 114 | 115 | 56 | 56 | 111 | 112 | 56 | 55 | 112 | 115 |
| Received treatment | 56 | 55 | 56 | 55 | 110 | 110 | 55 | 55 | 56 | 54 | 109 | 110 | 58 | 57 | 113 | 115 | 56 | 55 | 111 | 112 | 56 | 55 | 112 | 115 |
| Completed | 54 | 54 | 51 | 55 | 108 | 107 | 48 | 55 | 53 | 53 | 102 | 108 | 54 | 57 | 102 | 112 | 55 | 55 | 105 | 110 | 52 | 54 | 109 | 113 |
| Not completed | 2 | 1 | 5 | 0 | 2 | 3 | 7 | 0 | 3 | 1 | 8 | 2 | 4 | 0 | 12 | 3 | 1 | 1 | 6 | 2 | 4 | 1 | 3 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 | 4 | 0 | 0 | 3 | 4 | 0 | 1 | 1 | 2 | 2 | 2 | 0 | 6 | 3 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 1 |
| Withdrew: Decision by sponsor | 0 | 0 | 1 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 6 | 0 | 1 | 0 | 5 | 0 | 0 | 0 | 4 | 0 | 2 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 | 9.86 ± 2.53 | 0.97 ± 2.82 | -21.96 ± 2.63 | -17.08 ± 2.78 | -61.56 ± 1.81 | -58.19 ± 1.99 | 14.49 ± 4.42 | 11.83 ± 3.85 | -14.60 ± 4.29 | -19.80 ± 3.85 | -61.80 ± 3.04 | -58.68 ± 2.74 | 8.12 ± 2.68 | 5.10 ± 2.62 | -60.09 ± 1.94 | -59.40 ± 1.87 | 9.42 ± 3.60 | 2.59 ± 4.30 | -58.89 ± 2.58 | -52.40 ± 2.98 | 4.70 ± 3.61 | 3.40 ± 4.94 | -65.86 ± 3.05 | -57.02 ± 3.93 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | 8.54 ± 2.24 | 0.35 ± 2.60 | -23.88 ± 2.34 | -18.98 ± 2.57 | -61.41 ± 1.61 | -62.47 ± 1.83 | 13.12 ± 3.99 | 9.76 ± 3.39 | -16.85 ± 3.88 | -21.25 ± 3.42 | -61.80 ± 2.77 | -65.05 ± 2.42 | 7.55 ± 2.39 | 2.79 ± 2.50 | -59.33 ± 1.74 | -63.79 ± 1.76 | 6.57 ± 3.11 | -0.02 ± 3.51 | -59.08 ± 2.23 | -62.94 ± 2.44 | 3.26 ± 3.40 | 6.00 ± 4.80 | -66.17 ± 2.93 | -62.45 ± 3.85 |
| mg/dL | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12 | 6.8 ± 3.7 | -0.4 ± 4.4 | -32.4 ± 3.8 | -25.1 ± 4.3 | -76.8 ± 2.7 | -80.1 ± 3.1 | 11.0 ± 5.0 | 5.5 ± 3.7 | -13.0 ± 4.9 | -21.3 ± 3.7 | -58.8 ± 3.5 | -60.1 ± 2.6 | 6.5 ± 3.5 | 0.1 ± 4.2 | -68.9 ± 2.5 | -77.8 ± 3.0 | 3.4 ± 3.0 | -4.8 ± 4.2 | -52.3 ± 2.2 | -55.3 ± 2.9 | -5.7 ± 5.2 | 1.7 ± 6.5 | -83.8 ± 4.5 | -78.4 ± 5.1 |
| mg/dL | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in LDL-C at Week 12 | 8.6 ± 4.0 | 0.8 ± 4.5 | -30.1 ± 4.1 | -23.3 ± 4.5 | -77.0 ± 2.9 | -75.1 ± 3.2 | 12.7 ± 5.3 | 7.0 ± 4.1 | -9.9 ± 5.2 | -19.5 ± 4.1 | -59.0 ± 3.7 | -54.8 ± 2.9 | 7.8 ± 3.8 | 2.4 ± 4.4 | -69.2 ± 2.7 | -73.3 ± 3.1 | 5.1 ± 3.2 | -2.0 ± 4.7 | -52.1 ± 2.3 | -46.7 ± 3.3 | -4.5 ± 5.3 | -0.6 ± 6.6 | -83.5 ± 4.6 | -72.5 ± 5.2 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12 | 6.80 ± 2.07 | 1.28 ± 2.44 | -20.71 ± 2.15 | -16.56 ± 2.41 | -53.48 ± 1.48 | -56.09 ± 1.71 | 10.74 ± 3.59 | 8.45 ± 3.13 | -16.19 ± 3.49 | -18.79 ± 3.16 | -54.44 ± 2.49 | -56.31 ± 2.23 | 7.02 ± 2.11 | 3.73 ± 2.32 | -52.59 ± 1.54 | -55.47 ± 1.64 | 6.19 ± 2.61 | 1.58 ± 2.90 | -52.08 ± 1.88 | -55.72 ± 2.01 | 0.74 ± 3.23 | 6.81 ± 4.35 | -59.33 ± 2.79 | -56.01 ± 3.49 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 | 8.25 ± 2.32 | 2.43 ± 2.69 | -18.27 ± 2.40 | -14.78 ± 2.65 | -53.39 ± 1.66 | -52.20 ± 1.90 | 11.79 ± 3.87 | 9.95 ± 3.51 | -14.34 ± 3.75 | -17.26 ± 3.52 | -54.84 ± 2.66 | -50.05 ± 2.50 | 7.92 ± 2.40 | 5.85 ± 2.42 | -52.04 ± 1.74 | -51.57 ± 1.72 | 8.61 ± 3.04 | 3.35 ± 3.53 | -50.97 ± 2.18 | -46.42 ± 2.45 | 1.89 ± 3.38 | 5.66 ± 4.53 | -59.02 ± 2.87 | -50.96 ± 3.60 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12 | 7.55 ± 1.89 | 0.81 ± 2.19 | -17.29 ± 2.00 | -11.43 ± 2.20 | -50.95 ± 1.38 | -51.44 ± 1.52 | 10.20 ± 3.02 | 5.48 ± 2.83 | -14.22 ± 2.98 | -13.62 ± 2.87 | -49.14 ± 2.13 | -53.26 ± 2.02 | 5.07 ± 1.97 | 2.54 ± 1.89 | -49.79 ± 1.46 | -53.59 ± 1.32 | 3.71 ± 2.46 | 1.98 ± 2.57 | -47.07 ± 1.76 | -52.95 ± 1.76 | -0.31 ± 3.02 | 2.49 ± 4.67 | -55.65 ± 2.63 | -54.37 ± 3.93 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 12 | 7.89 ± 2.16 | 0.21 ± 2.43 | -15.98 ± 2.26 | -10.95 ± 2.44 | -50.90 ± 1.56 | -47.15 ± 1.70 | 11.64 ± 3.28 | 6.54 ± 3.22 | -12.31 ± 3.20 | -12.16 ± 3.24 | -49.77 ± 2.28 | -46.47 ± 2.31 | 6.35 ± 2.10 | 4.63 ± 2.11 | -50.15 ± 1.54 | -48.58 ± 1.49 | 4.91 ± 2.71 | 3.24 ± 3.13 | -45.61 ± 1.93 | -43.71 ± 2.13 | 0.35 ± 3.17 | 3.57 ± 4.74 | -55.95 ± 2.72 | -49.16 ± 3.97 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12 | 5.96 ± 1.76 | 2.24 ± 2.11 | -14.39 ± 1.83 | -10.86 ± 2.08 | -40.44 ± 1.26 | -42.45 ± 1.48 | 4.26 ± 2.59 | 6.42 ± 2.34 | -11.92 ± 2.52 | -12.25 ± 2.35 | -40.22 ± 1.80 | -40.43 ± 1.66 | 5.41 ± 1.96 | 5.02 ± 2.25 | -39.33 ± 1.43 | -42.00 ± 1.59 | 4.55 ± 1.98 | 1.71 ± 2.36 | -36.04 ± 1.42 | -38.62 ± 1.64 | -0.14 ± 2.79 | 5.45 ± 3.50 | -47.20 ± 2.37 | -43.17 ± 2.85 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12 | 6.09 ± 2.02 | 2.80 ± 2.31 | -12.14 ± 2.10 | -9.85 ± 2.28 | -40.74 ± 1.45 | -40.07 ± 1.63 | 4.31 ± 2.75 | 6.18 ± 2.73 | -10.53 ± 2.66 | -11.06 ± 2.73 | -40.79 ± 1.89 | -36.25 ± 1.94 | 4.68 ± 2.28 | 6.07 ± 2.36 | -38.57 ± 1.64 | -39.26 ± 1.68 | 5.96 ± 2.28 | 2.69 ± 2.80 | -35.17 ± 1.63 | -32.30 ± 1.94 | -0.20 ± 2.81 | 5.13 ± 3.62 | -47.24 ± 2.38 | -39.47 ± 2.92 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12 | 6.41 ± 2.03 | 0.78 ± 2.29 | -15.77 ± 2.14 | -11.47 ± 2.29 | -53.56 ± 1.48 | -53.33 ± 1.58 | 4.48 ± 3.04 | 5.79 ± 2.79 | -15.17 ± 2.99 | -12.91 ± 2.80 | -52.43 ± 2.14 | -56.20 ± 1.98 | 2.82 ± 2.26 | 2.58 ± 2.05 | -52.46 ± 1.67 | -56.66 ± 1.43 | 2.17 ± 2.56 | 2.60 ± 2.97 | -48.47 ± 1.83 | -54.17 ± 2.04 | -1.00 ± 3.12 | -1.42 ± 4.22 | -58.76 ± 2.73 | -57.47 ± 3.55 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12 | 6.13 ± 2.20 | -1.21 ± 2.41 | -14.51 ± 2.31 | -12.33 ± 2.41 | -54.17 ± 1.59 | -49.65 ± 1.69 | 4.19 ± 3.25 | 6.50 ± 3.18 | -13.69 ± 3.17 | -12.19 ± 3.17 | -53.59 ± 2.26 | -50.76 ± 2.26 | 1.44 ± 2.30 | 4.00 ± 2.27 | -52.97 ± 1.69 | -52.13 ± 1.60 | 1.64 ± 2.75 | 3.16 ± 3.51 | -47.53 ± 1.96 | -45.65 ± 2.39 | -1.80 ± 3.21 | -0.52 ± 4.29 | -59.53 ± 2.77 | -52.56 ± 3.59 |
| percentage of participants | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL | 5.7 (1.9 to 15.4) | 5.6 (1.9 to 15.1) | 20.0 (11.2 to 33.0) | 16.7 (9.0 to 28.7) | 88.1 (80.7 to 92.9) | 85.8 (78.0 to 91.2) | 13.7 (6.8 to 25.7) | 9.3 (4.0 to 19.9) | 50.9 (38.1 to 63.6) | 62.3 (48.8 to 74.1) | 94.4 (88.4 to 97.4) | 92.5 (85.9 to 96.2) | 7.0 (2.8 to 16.7) | 5.3 (1.8 to 14.4) | 88.7 (81.2 to 93.4) | 89.9 (82.8 to 94.3) | 38.9 (27.0 to 52.2) | 28.8 (18.3 to 42.3) | 93.5 (87.1 to 96.8) | 94.5 (88.6 to 97.5) | 1.9 (0.3 to 9.8) | 3.9 (1.1 to 13.2) | 93.6 (87.3 to 96.9) | 88.5 (81.3 to 93.2) |
| percentage of participants | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12 | 2.0 (0.3 to 10.3) | 5.9 (2.0 to 15.9) | 22.4 (13.0 to 35.9) | 19.2 (10.8 to 31.9) | 85.4 (77.4 to 91.0) | 84.2 (75.8 to 90.0) | 13.0 (6.1 to 25.7) | 9.8 (4.3 to 21.0) | 52.0 (38.5 to 65.2) | 55.8 (42.3 to 68.4) | 93.1 (86.5 to 96.6) | 91.0 (83.8 to 95.2) | 7.7 (3.0 to 18.2) | 5.5 (1.9 to 14.9) | 85.0 (76.7 to 90.7) | 86.5 (78.7 to 91.8) | 39.6 (27.6 to 53.1) | 28.0 (17.5 to 41.7) | 92.3 (85.6 to 96.1) | 92.3 (85.6 to 96.1) | 1.9 (0.3 to 10.1) | 6.4 (2.2 to 17.2) | 94.4 (88.4 to 97.4) | 84.8 (76.7 to 90.4) |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12 | 6.07 ± 2.86 | -0.77 ± 3.28 | 1.44 ± 3.02 | 6.85 ± 3.29 | -26.01 ± 2.08 | -22.64 ± 2.27 | -3.45 ± 2.99 | 1.51 ± 3.35 | 8.05 ± 2.94 | 9.96 ± 3.40 | -23.97 ± 2.10 | -27.46 ± 2.39 | 11.41 ± 3.00 | 3.65 ± 3.56 | -24.26 ± 2.21 | -23.16 ± 2.50 | 8.59 ± 2.98 | 6.26 ± 3.59 | -24.96 ± 2.12 | -25.93 ± 2.46 | -10.57 ± 4.49 | -4.99 ± 5.37 | -38.64 ± 3.92 | -32.16 ± 4.50 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 12 | 7.34 ± 3.13 | -0.43 ± 3.38 | 3.29 ± 3.28 | 7.18 ± 3.38 | -25.87 ± 2.26 | -20.25 ± 2.36 | -2.23 ± 3.35 | 3.41 ± 3.54 | 8.01 ± 3.26 | 10.20 ± 3.57 | -24.61 ± 2.31 | -24.68 ± 2.53 | 11.40 ± 3.37 | 4.49 ± 3.68 | -25.09 ± 2.47 | -20.85 ± 2.59 | 10.38 ± 3.09 | 10.21 ± 4.36 | -26.11 ± 2.21 | -21.97 ± 2.97 | -6.81 ± 4.57 | -1.06 ± 5.67 | -38.06 ± 3.96 | -29.23 ± 4.68 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12 | 6.49 ± 3.94 | 9.17 ± 4.41 | -3.16 ± 4.10 | 1.57 ± 4.35 | -5.61 ± 2.81 | -13.38 ± 3.08 | 6.16 ± 4.02 | 8.05 ± 4.35 | -8.10 ± 3.92 | -4.86 ± 4.39 | -9.27 ± 2.80 | -6.36 ± 3.11 | 12.43 ± 4.19 | 12.26 ± 4.67 | -10.28 ± 3.04 | -7.26 ± 3.29 | 8.44 ± 3.76 | 10.75 ± 3.98 | -9.15 ± 2.70 | -15.43 ± 2.77 | 9.29 ± 6.97 | 13.78 ± 7.44 | -11.67 ± 5.97 | -15.93 ± 6.15 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 12 | 8.27 ± 5.23 | 14.35 ± 5.92 | -0.43 ± 5.39 | 4.88 ± 5.84 | -3.79 ± 3.72 | -13.26 ± 4.17 | 6.65 ± 4.45 | 8.22 ± 5.22 | -7.40 ± 4.32 | -3.11 ± 5.23 | -10.07 ± 3.05 | -1.10 ± 3.74 | 13.57 ± 5.76 | 12.96 ± 5.32 | -4.46 ± 4.16 | -6.88 ± 3.80 | 10.97 ± 4.66 | 10.00 ± 4.38 | -5.58 ± 3.34 | -10.51 ± 3.04 | 8.07 ± 6.88 | 16.72 ± 7.88 | -13.71 ± 5.91 | -14.65 ± 6.39 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12 | 6.51 ± 3.56 | 9.53 ± 4.45 | -5.35 ± 3.74 | 1.77 ± 4.41 | -6.85 ± 2.56 | -11.77 ± 3.11 | 6.24 ± 4.03 | 8.31 ± 4.26 | -8.52 ± 3.93 | -6.13 ± 4.31 | -8.96 ± 2.82 | -6.38 ± 3.05 | 12.86 ± 3.95 | 12.54 ± 4.58 | -12.22 ± 2.86 | -7.25 ± 3.23 | 7.06 ± 3.76 | 8.13 ± 3.72 | -9.09 ± 2.71 | -15.05 ± 2.58 | 8.64 ± 6.01 | 16.37 ± 7.15 | -14.57 ± 5.17 | -16.50 ± 5.87 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12 | 8.32 ± 4.00 | 14.74 ± 5.91 | -4.61 ± 4.19 | 3.45 ± 5.89 | -6.16 ± 2.88 | -11.73 ± 4.16 | 6.73 ± 4.45 | 8.54 ± 5.00 | -7.92 ± 4.32 | -6.00 ± 5.04 | -9.69 ± 3.05 | -1.06 ± 3.58 | 13.79 ± 5.05 | 12.47 ± 5.31 | -8.20 ± 3.64 | -6.28 ± 3.78 | 10.09 ± 4.65 | 8.59 ± 4.37 | -6.10 ± 3.33 | -9.95 ± 3.03 | 7.63 ± 6.26 | 20.97 ± 7.53 | -14.83 ± 5.30 | -15.86 ± 6.09 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12 | -0.99 ± 1.50 | -0.45 ± 1.94 | -1.13 ± 1.56 | -0.92 ± 1.92 | 5.54 ± 1.07 | 7.66 ± 1.37 | 4.48 ± 1.73 | -1.37 ± 1.85 | 0.86 ± 1.68 | -0.59 ± 1.86 | 8.44 ± 1.20 | 7.76 ± 1.31 | 0.87 ± 1.52 | -0.94 ± 2.55 | 6.23 ± 1.10 | 7.72 ± 1.80 | -0.60 ± 1.56 | -0.40 ± 1.81 | 4.86 ± 1.12 | 6.35 ± 1.26 | 0.13 ± 2.75 | -2.14 ± 2.72 | 10.35 ± 2.26 | 6.71 ± 2.25 |
| percent change | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 | 0.22 ± 1.72 | 0.01 ± 2.02 | -1.76 ± 1.78 | -0.40 ± 1.99 | 7.04 ± 1.23 | 7.88 ± 1.42 | 5.02 ± 1.88 | 0.30 ± 2.01 | 0.62 ± 1.83 | 0.21 ± 2.01 | 9.09 ± 1.29 | 7.36 ± 1.43 | 2.87 ± 1.87 | -0.16 ± 2.64 | 6.07 ± 1.35 | 7.18 ± 1.87 | -0.39 ± 1.86 | 0.73 ± 1.98 | 4.65 ± 1.34 | 5.57 ± 1.37 | 1.14 ± 2.96 | -2.65 ± 2.87 | 10.92 ± 2.38 | 6.41 ± 2.34 |
Collected over From the first dose of blinded investigational product until the end of the study (up to 14 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A10 PBO Q2W | — | 1/56 (1.8%) | 5/56 (8.9%) |
| A10 PBO QM | — | 2/55 (3.6%) | 3/55 (5.5%) |
| A10 EZE (Q2W) | — | 0/56 (0%) | 9/56 (16.1%) |
| A10 EZE (QM) | — | 0/55 (0%) | 6/55 (10.9%) |
| A10 EvoMab Q2W | — | 4/110 (3.6%) | 9/110 (8.2%) |
| A10 EvoMab QM | — | 2/110 (1.8%) | 7/110 (6.4%) |
| A80 PBO Q2W | — | 2/55 (3.6%) | 7/55 (12.7%) |
| A80 PBO QM | — | 1/55 (1.8%) | 13/55 (23.6%) |
| A80 EZE (Q2W) | — | 1/56 (1.8%) | 8/56 (14.3%) |
| A80 EZE (QM) | — | 1/54 (1.9%) | 2/54 (3.7%) |
| A80 EvoMab Q2W | — | 3/109 (2.8%) | 11/109 (10.1%) |
| A80 EvoMab QM | — | 1/110 (0.9%) | 9/110 (8.2%) |
| R5 PBO Q2W | — | 1/58 (1.7%) | 11/58 (19%) |
| R5 PBO QM | — | 2/57 (3.5%) | 1/57 (1.8%) |
| R5 EvoMab Q2W | — | 3/113 (2.7%) | 6/113 (5.3%) |
| R5 EvoMab QM | — | 3/115 (2.6%) | 9/115 (7.8%) |
| R40 PBO Q2W | — | 2/56 (3.6%) | 3/56 (5.4%) |
| R40 PBO QM | — | 1/55 (1.8%) | 8/55 (14.5%) |
| R40 EvoMab Q2W | — | 1/111 (0.9%) | 5/111 (4.5%) |
| R40 EvoMab QM | — | 3/112 (2.7%) | 8/112 (7.1%) |
| S40 PBO Q2W | — | 0/56 (0%) | 3/56 (5.4%) |
| S40 PBO QM | — | 1/55 (1.8%) | 5/55 (9.1%) |
| S40 EvoMab Q2W | — | 2/112 (1.8%) | 18/112 (16.1%) |
| S40 EvoMab QM | — | 1/115 (0.9%) | 11/115 (9.6%) |
| Event | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Troponin increasedInvestigations | 0/56 | 0/55 | 0/56 | 0/55 | 0/110 | 0/110 | 0/55 | 0/55 | 0/56 | 1/54 | 0/109 | 0/110 | 0/58 | 0/57 | 0/113 | 0/115 | 0/56 | 0/55 | 0/111 | 0/112 | 0/56 | 0/55 | 0/112 | 0/115 |
| Hypertensive crisisVascular disorders | 0/56 | 0/55 | 0/56 | 0/55 | 0/110 | 0/110 | 0/55 | 0/55 | 0/56 | 1/54 | 0/109 | 0/110 | 0/58 | 0/57 | 0/113 | 0/115 | 0/56 | 0/55 | 0/111 | 0/112 | 0/56 | 0/55 | 0/112 | 0/115 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/56 | 0/55 | 0/56 | 0/55 | 0/110 | 0/110 | 1/55 | 0/55 | 0/56 | 0/54 | 0/109 | 0/110 | 0/58 | 0/57 | 0/113 | 0/115 | 0/56 | 1/55 | 0/111 | 0/112 | 0/56 | 0/55 | 0/112 | 0/115 |
| Drug-induced liver injuryHepatobiliary disorders | 0/56 | 1/55 | 0/56 | 0/55 | 0/110 | 0/110 | 0/55 | 0/55 | 0/56 | 0/54 | 0/109 | 0/110 | 0/58 | 0/57 | 0/113 | 0/115 | 0/56 | 0/55 | 0/111 | 0/112 | 0/56 | 0/55 | 0/112 | 0/115 |
| GastroenteritisInfections and infestations | 0/56 | 0/55 | 0/56 | 0/55 | 0/110 | 0/110 | 1/55 | 0/55 | 0/56 | 0/54 | 0/109 | 0/110 | 0/58 | 0/57 | 0/113 | 0/115 | 0/56 | 0/55 | 0/111 | 0/112 | 0/56 | 0/55 | 0/112 | 0/115 |
| Herpes simplex meningoencephalitisInfections and infestations | 0/56 | 0/55 | 0/56 | 0/55 | 0/110 | 0/110 | 1/55 | 0/55 | 0/56 | 0/54 | 0/109 | 0/110 | 0/58 | 0/57 | 0/113 | 0/115 | 0/56 | 0/55 | 0/111 | 0/112 | 0/56 | 0/55 | 0/112 | 0/115 |
| Pneumonia mycoplasmalInfections and infestations | 0/56 | 1/55 | 0/56 | 0/55 | 0/110 | 0/110 | 0/55 | 0/55 | 0/56 | 0/54 | 0/109 | 0/110 | 0/58 | 0/57 | 0/113 | 0/115 | 0/56 | 0/55 | 0/111 | 0/112 | 0/56 | 0/55 | 0/112 | 0/115 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/56 | 0/55 | 0/56 | 0/55 | 0/110 | 0/110 | 0/55 | 1/55 | 0/56 | 0/54 | 0/109 | 0/110 | 0/58 | 0/57 | 0/113 | 0/115 | 0/56 | 0/55 | 0/111 | 0/112 | 0/56 | 0/55 | 0/112 | 0/115 |
| Grand mal convulsionNervous system disorders | 0/56 | 0/55 | 0/56 | 0/55 | 0/110 | 0/110 | 1/55 | 0/55 | 0/56 | 0/54 | 0/109 | 0/110 | 0/58 | 0/57 | 0/113 | 0/115 | 0/56 | 0/55 | 0/111 | 0/112 | 0/56 | 0/55 | 0/112 | 0/115 |
| Peripheral artery stenosisVascular disorders | 0/56 | 0/55 | 0/56 | 0/55 | 0/110 | 0/110 | 0/55 | 0/55 | 0/56 | 0/54 | 0/109 | 0/110 | 0/58 | 0/57 | 0/113 | 0/115 | 0/56 | 0/55 | 0/111 | 0/112 | 0/56 | 1/55 | 0/112 | 0/115 |
| Event | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/56 | 0/55 | 3/56 | 1/55 | 2/110 | 1/110 | 2/55 | 2/55 | 2/56 | 1/54 | 3/109 | 0/110 | 4/58 | 0/57 | 1/113 | 2/115 | 0/56 | 5/55 | 2/111 | 1/112 | 0/56 | 1/55 | 6/112 | 2/115 |
| DiarrhoeaGastrointestinal disorders | 0/56 | 0/55 | 0/56 | 1/55 | 2/110 | 0/110 | 1/55 | 4/55 | 1/56 | 0/54 | 4/109 | 2/110 | 0/58 | 1/57 | 0/113 | 2/115 | 1/56 | 1/55 | 0/111 | 1/112 | 0/56 | 1/55 | 1/112 | 0/115 |
| HeadacheNervous system disorders | 1/56 | 1/55 | 1/56 | 4/55 | 1/110 | 0/110 | 2/55 | 2/55 | 0/56 | 0/54 | 1/109 | 3/110 | 3/58 | 0/57 | 1/113 | 1/115 | 2/56 | 1/55 | 2/111 | 3/112 | 2/56 | 1/55 | 2/112 | 5/115 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/56 | 2/55 | 2/56 | 0/55 | 0/110 | 1/110 | 0/55 | 3/55 | 1/56 | 1/54 | 1/109 | 2/110 | 1/58 | 0/57 | 0/113 | 2/115 | 0/56 | 1/55 | 1/111 | 1/112 | 0/56 | 1/55 | 1/112 | 3/115 |
| ConstipationGastrointestinal disorders | 3/56 | 0/55 | 0/56 | 0/55 | 0/110 | 0/110 | 1/55 | 0/55 | 1/56 | 0/54 | 0/109 | 0/110 | 0/58 | 0/57 | 1/113 | 0/115 | 0/56 | 0/55 | 0/111 | 0/112 | 0/56 | 0/55 | 2/112 | 0/115 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/56 | 0/55 | 1/56 | 2/55 | 3/110 | 4/110 | 1/55 | 2/55 | 3/56 | 0/54 | 2/109 | 1/110 | 1/58 | 0/57 | 2/113 | 0/115 | 0/56 | 1/55 | 0/111 | 1/112 | 0/56 | 1/55 | 3/112 | 1/115 |
| DizzinessNervous system disorders | 0/56 | 0/55 | 2/56 | 1/55 | 1/110 | 1/110 | 1/55 | 1/55 | 1/56 | 1/54 | 0/109 | 1/110 | 3/58 | 0/57 | 1/113 | 2/115 | 0/56 | 0/55 | 0/111 | 1/112 | 1/56 | 0/55 | 3/112 | 1/115 |
| Age, Continuous(years) | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 58.3 ± 10.5 | 62.2 ± 10.4 | 61.0 ± 9.0 | 60.6 ± 9.2 | 58.3 ± 8.4 | 59.6 ± 11.1 | 57.1 ± 9.9 | 58.8 ± 11.5 | 60.5 ± 10.2 | 61.1 ± 8.9 | 59.7 ± 10.2 | 60.1 ± 10.2 | 61.2 ± 9.1 | 59.6 ± 9.2 | 58.9 ± 11.2 | 59.3 ± 10.5 | 60.2 ± 8.7 | 58.3 ± 11.3 | 59.5 ± 9.2 | 59.6 ± 9.0 | 61.9 ± 9.7 | 61.5 ± 10.3 | 59.7 ± 9.2 | 61.5 ± 9.6 | 59.8 ± 9.9 |
| Sex: Female, Male(Participants) | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 24 | 28 | 29 | 28 | 56 | 44 | 22 | 24 | 24 | 28 | 44 | 48 | 35 | 27 | 52 | 51 | 21 | 27 | 43 | 52 | 32 | 28 | 45 | 59 | 871 |
| Male | 32 | 27 | 27 | 27 | 54 | 66 | 33 | 31 | 32 | 26 | 66 | 62 | 23 | 30 | 62 | 64 | 35 | 29 | 68 | 60 | 24 | 27 | 67 | 56 | 1028 |
| Race/Ethnicity, Customized(participants) | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 2 | 1 | 5 | 2 | 5 | 5 | 4 | 4 | 5 | 7 | 2 | 4 | 6 | 3 | 2 | 3 | 6 | 5 | 1 | 2 | 3 | 5 | 87 |
| Not Hispanic or Latino | 53 | 53 | 54 | 54 | 105 | 108 | 50 | 50 | 52 | 50 | 105 | 103 | 56 | 53 | 108 | 112 | 54 | 53 | 105 | 107 | 55 | 53 | 109 | 110 | 1812 |
| Race/Ethnicity, Customized(participants) | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 1 | 0 | 2 | 1 | 3 | 4 | 1 | 0 | 0 | 3 | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 25 |
| Black or African American | 3 | 0 | 1 | 2 | 9 | 4 | 1 | 2 | 3 | 4 | 3 | 4 | 2 | 1 | 7 | 5 | 0 | 3 | 5 | 3 | 3 | 1 | 4 | 5 | 75 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 4 |
| White | 52 | 55 | 53 | 52 | 97 | 101 | 51 | 52 | 53 | 46 | 105 | 105 | 56 | 56 | 104 | 107 | 55 | 52 | 105 | 109 | 49 | 54 | 106 | 110 | 1785 |
| Other | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| Mixed Race | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Stratification Factor: Entry Statin Therapy(participants) | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intensive statin use | 18 | 19 | 10 | 14 | 28 | 35 | 15 | 12 | 21 | 11 | 34 | 35 | 13 | 13 | 33 | 38 | 13 | 13 | 33 | 37 | 19 | 13 | 31 | 34 | 542 |
| Non-intensive statin use | 20 | 25 | 30 | 21 | 52 | 40 | 22 | 27 | 22 | 21 | 47 | 46 | 25 | 28 | 49 | 42 | 23 | 22 | 50 | 44 | 21 | 26 | 45 | 48 | 796 |
| No statin use | 18 | 11 | 16 | 20 | 30 | 35 | 18 | 16 | 13 | 22 | 29 | 29 | 20 | 16 | 32 | 35 | 20 | 21 | 28 | 31 | 16 | 16 | 36 | 33 | 561 |
| Low-Density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL) | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 123.0 ± 46.6 | 123.7 ± 47.9 | 126.8 ± 49.6 | 119.3 ± 28.1 | 124.2 ± 43.4 | 126.1 ± 50.4 | 100.3 ± 36.2 | 94.7 ± 31.9 | 98.7 ± 34.0 | 92.3 ± 19.3 | 94.2 ± 34.8 | 93.8 ± 32.3 | 115.6 ± 39.8 | 119.9 ± 39.1 | 118.7 ± 40.9 | 122.9 ± 42.0 | 77.4 ± 20.9 | 102.9 ± 49.3 | 88.5 ± 31.5 | 88.5 ± 31.3 | 110.3 ± 28.0 | 108.6 ± 30.9 | 114.9 ± 34.5 | 123.7 ± 48.5 | 109.1 ± 41.1 |
| Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL) | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 149.1 ± 46.9 | 147.7 ± 51.4 | 153.8 ± 53.2 | 148.3 ± 36.8 | 152.3 ± 45.6 | 154.3 ± 53.1 | 124.2 ± 39.3 | 116.5 ± 35.7 | 124.8 ± 35.4 | 118.4 ± 25.5 | 120.2 ± 42.3 | 117.2 ± 36.3 | 141.1 ± 41.6 | 148.3 ± 43.3 | 146.6 ± 43.2 | 152.0 ± 46.4 | 103.9 ± 25.7 | 128.7 ± 53.4 | 113.5 ± 36.0 | 114.3 ± 34.7 | 138.4 ± 29.3 | 135.7 ± 38.4 | 146.8 ± 41.8 | 151.2 ± 51.5 | 150.3 ± 27.6 |
| Apolipoprotein B Concentration(mg/dL) | A10 PBO Q2W | A10 PBO QM | A10 EZE (Q2W) | A10 EZE (QM) | A10 EvoMab Q2W | A10 EvoMab QM | A80 PBO Q2W | A80 PBO QM | A80 EZE (Q2W) | A80 EZE (QM) | A80 EvoMab Q2W | A80 EvoMab QM | R5 PBO Q2W | R5 PBO QM | R5 EvoMab Q2W | R5 EvoMab QM | R40 PBO Q2W | R40 PBO QM | R40 EvoMab Q2W | R40 EvoMab QM | S40 PBO Q2W | S40 PBO QM | S40 EvoMab Q2W | S40 EvoMab QM | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 95.3 ± 26.0 | 95.3 ± 29.6 | 101.3 ± 31.2 | 94.6 ± 20.4 | 99.7 ± 26.4 | 97.3 ± 28.9 | 81.1 ± 22.1 | 80.1 ± 21.4 | 85.3 ± 23.1 | 78.7 ± 16.9 | 79.9 ± 25.1 | 77.9 ± 21.5 | 93.1 ± 27.3 | 95.9 ± 25.2 | 95.4 ± 27.0 | 97.2 ± 26.9 | 71.0 ± 16.6 | 84.8 ± 29.7 | 77.4 ± 22.3 | 78.7 ± 23.1 | 91.6 ± 18.4 | 89.8 ± 20.7 | 94.2 ± 24.0 | 96.5 ± 27.5 | 89.1 ± 26.1 |
6 further baseline measures are reported on the registry.
Showing the first 100 of 244 sites across 21 countries. Choose a country and city above to see the rest.
Ran from Jan 2013 to primary completion in Nov 2013, 9 months.
Results were first posted in Dec 2015, 2 years 1 month after primary completion. A results delay was requested in May 2014.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Evolocumab · Atorvastatin · Rosuvastatin · Simvastatin